Bivalirudin Infusion for Ventricular Infarction Limitation
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 78
- Registration Number
- NCT02565147
- Locations
- 🇫🇷
Hopital Ambroise Paré, Boulogne Cedex, France
🇫🇷Hospital Lariboisière, Paris, France
🇳🇱VUMC Amsterdam, Amsterdam, Netherlands
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 56
- Registration Number
- NCT02471690
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 17
- Registration Number
- NCT02452918
Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 71
- Registration Number
- NCT02395653
- Locations
- 🇺🇸
Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Association Between Patients' Perceptions of Success in Post-op Pain Management and Overall Experience With Care
- Conditions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- The Medicines Company
- Registration Number
- NCT02389907
- Locations
- 🇺🇸
Phoenix Clinical Research LLC, Tamarac, Florida, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Magee-Women's Hospital (UPMC), Pittsburgh, Pennsylvania, United States
Cangrelor to Clopidogrel or Prasugrel Transition Study
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 15
- Registration Number
- NCT01979445
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial
- Conditions
- Interventions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 732
- Registration Number
- NCT01913483
- Locations
- 🇺🇸
Clearwater Cardiovascular and Interventional Consultants, Clearwater, Florida, United States
🇺🇸Deborah Heart and Lung Center, Browns Mills, New Jersey, United States
🇺🇸Stony Brook Medicine, Stony Brook, New York, United States
Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation
- Conditions
- Interventions
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 37
- Registration Number
- NCT01860105
- Locations
- 🇫🇷
Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Cangrelor Prasugrel Transition Study
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 12
- Registration Number
- NCT01852019
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
Cangrelor Ticagrelor Transition Study
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 12
- Registration Number
- NCT01766466
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States